Release – Chakana Copper Announces Filing Of Technical Report For Previously Reported Inferred Mineral Resources For Soledad Project Peru



Chakana Copper Announces Filing Of Technical Report For Previously Reported Inferred Mineral Resources For Soledad Project, Peru

Research, News, and Market Data on Chakana Copper

 

Vancouver, B.C., February 23, 2022 – Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), announced today that the corporation has filed on SEDAR a technical report prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Project (“NI-43-101”) supporting the inferred mineral resource statement for the Soledad Project located in Ancash, Peru. The highlights of the Report were previously announced in a news release dated January 11, 2022, and the effective date of the Report is January 3, 2022. The technical report, titled “Independent Technical Report for the Soledad Copper Project, Ancash Department, Peru”, can be found under the Corporation’s issuer profile at www.sedar.com.

Highlights of the Mineral Resource Estimate:

  • Inferred Resources were estimated for seven breccia pipes that start at surface and extend to an average depth of approximately 300 metres; all zones remain open at depth
  • Inferred Resources of 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper assumed to be extractable by underground mining methods
  • Inferred Resources of 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper assumed to be extractable by open pit mining methods
  • The total initial Inferred Resource contains 191,000 ounces of gold, 11.7 million ounces of silver, and 130 million pounds of copper
  • Opportunities for increasing the Inferred Resources include drill testing numerous additional breccia pipes and other targets identified on the property and extending the known mineralized zones at depth from the current Inferred Resources
  • Only 16 out of 110 (15%) current targets have been tested to date, seven of which are included in the initial Inferred Resource estimate; several of the tested targets are mineralized but not yet included in the initial Inferred Resource as they require additional definition drilling

As previously reported, copper-gold-silver mineralization at the Soledad project is hosted within multiple, vertically extensive tourmaline breccia pipes; important minerals are chalcopyrite, gold, electrum, and tetrahedrite. The resource estimate confirms that the tourmaline breccia pipes at Soledad host significant mineralization with good continuity. The pipes exhibit strong zonation between gold, copper, and silver. Drilling has confirmed the existence of blind breccia pipes that do not crop out a surface (Bx 1 North Zone), and breccia pipes that do crop out coalescing into larger breccias at depth (Huancarama East). The resource model, when combined with our other exploration data sets, helps refine the targeting model that will be used in future exploration drilling campaigns.

“This initial Inferred Resource is a blueprint for the much larger potential of the expanded Soledad project that now covers 4,200 hectares. Our ongoing exploration has defined numerous high-quality drill targets across the broader Soledad project. The Offset (3D) IP geophysical survey we are currently running has been particularly useful in defining targets with larger footprints, consistent with the signature of the larger breccia pipes we have drilled so far. We are excited about testing the broader exploration potential of the project and continuing our ESG programs that have matured over the last couple of years,” stated President and CEO David Kelley.

Mineral resources were estimated by W.F. Tanaka (FAusIMM) and audited and accepted by Dr. Gilles Arseneau (PGeo.) of ARSENEAU Consulting Services Inc. of Vancouver. Resources were estimated for seven tourmaline breccias by ordinary kriging into 5 by 5 by 10 m blocks. Grades were composited to 5 m length and silver composites were capped at 500 g/t for Breccia 1 and 720 g/t for Breccia 6.  

The mineral resources were estimated in accordance with the CIM Definition Standards on Mineral Resources and Mineral Reserves adopted by CIM Council, as amended, and in accordance with National Instrument 43-101.  Near surface mineral resources were reported inside an optimized pit shell and at a dollar equivalent cut-off of US$ 25.00. The dollar equivalent is calculated using a US$1,600 per ounce for gold, US$20 per ounce for silver, and US$3.50 per pound for copper. Metallurgical recoveries were assumed to be 85% for gold, 75% for silver and 90% for copper. Material not captured by the optimized pit shell was assumed to be extractable by underground mining methods if the blocks were above a US$60 cut-off and represented a shape amenable to underground mining below the pit shell. Lead and zinc values also present at Soledad were not considered in the equivalent calculation.

 Based on the above parameters, ACS estimated that the Soledad Project contains 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper amenable to extraction by underground mining methods plus an additional 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper amenable to extraction by open pit mining methods.  All resources are classified as Inferred mineral resource as the term is defined by CIM. The QP is not aware of any known legal, political, environmental, or other risks that could materially affect the potential development of the mineral resources or mineral reserves per section 3.4(d) of 43-101.

Soledad Project – Inferred Mineral Resource Statement ACS, effective January 3, 2022  

 Cut -Off (US$)^

Type

Breccia

Tonnes*

Au (g/t)

Ag (g/t)

Cu (%)

$25.00

Open Pit

Breccia 1

486,000

2.46

58.7

1.08

$25.00

Open Pit

Breccia 5

612,000

1.34

22.7

0.44

$25.00

Open Pit

Breccia 6

19,000

0.59

60.7

0.03

$25.00

Open Pit

Breccia 7

76,000

0.65

13.1

0.32

$25.00

Open Pit

Huancarama E

386,000

0.32

40.1

0.42

$25.00

Open Pit

Paloma E

141,000

0.61

18.2

0.35

$25.00

Open Pit

Paloma W

169,000

0.85

44.0

1.12

$25.00

Open Pit Total

All Pipes

1,889,000

1.29

37.1

0.65

$60.00

Underground

Breccia 1

2,170,000

0.65

85.7

1.24

$60.00

Underground

Breccia 5

1,045,000

1.08

13.6

0.86

$60.00

Underground

Breccia 6

114,000

1.28

88.5

0.29

$60.00

Underground

Breccia 7

177,000

0.78

103.7

0.11

$60.00

Underground

Huancarama E

1,185,000

0.52

53.5

0.79

$60.00

Underground

Paloma E

82,000

0.22

23.3

0.68

$60.00

Underground

Paloma W

67,000

0.59

17.0

0.78

$60.00

Underground Total

All Pipes

4,842,000

0.72

61.0

0.97

 

Open Pit + UG

All Pipes

6,731,000

0.88

54.2

0.88

 *Numbers may not add up exactly due to rounding; ^ Cut-offs are based on $1,600/oz gold, $20/oz silver, and $3.50 /lb copper and assumed recoveries of 90% for copper, 85% for gold, and 75% for silver.

Qualified Persons

The Mineral Resource Estimate for the Soledad Project was prepared by Dr. Gilles Arseneau of Arseneau Consulting Services (ACS), an Independent Qualified Person (“QP”) as defined under NI 43-101, who has reviewed and approved the contents of this news release. The technical content of this news release has been reviewed and approved by David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101– Standards of Disclosure of Mineral Projects.

Sampling and Analytical Procedures
All core is cut in half and sampled in one-metre intervals within a secured area until transport in batches to the ALS facility in Callao, Lima, Peru.  Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24.  Over limit silver, copper, lead, and zinc are analyzed using the OG-46 procedure.

Results of previous drilling and additional information concerning the Project are available on Chakana’s SEDAR profile at www.sedar.com.

ON BEHALF OF THE BOARD

(signed) “David Kelley”  
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone: 647 964 0292
Email: jjobin@chakanacopper.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statement Advisory: This release may contain forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Chakana to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, the interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the “Project”), the potential to expand the mineralization, and to develop and grow a resource within the Project, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our belief in the potential for mineralization within unexplored parts of the Project. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward- looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.

Ayala Pharmaceuticals (AYLA) – Ayala Completes Phase 2/3 Trial RINGSIDE Part A and Confirms Data Milestone

Thursday, February 24, 2022

Ayala Pharmaceuticals (AYLA)
Ayala Completes Phase 2/3 Trial RINGSIDE Part A and Confirms Data Milestone

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First Stage of Phase 2/3 RINGSIDE Trial Completed Enrollment.  Ayala has announced that enrollment is complete for Part A of the Phase 2/3 RINGSIDE trial. This trial is testing the oral gamma-secretase inhibitor, AL102, in desmoid tumors. The data from this portion of the trial is expected to be announced in mid-2022, consistent with prior guidance.

    Part A Is Designed To Determine Safety, Efficacy, and Dosing For Part B.  The first part of the RINGSIDE trial enrolled 36 patients to evaluate safety, tolerability, and changes in tumor volume by MRI scans. These data will be used to select the dose for Part B. A previous sub-study tested pharmacokinetics and found no food restrictions were needed …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Ayala Pharmaceuticals (AYLA) – Ayala Completes Phase 2 3 Trial RINGSIDE Part A and Confirms Data Milestone

Thursday, February 24, 2022

Ayala Pharmaceuticals (AYLA)
Ayala Completes Phase 2/3 Trial RINGSIDE Part A and Confirms Data Milestone

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First Stage of Phase 2/3 RINGSIDE Trial Completed Enrollment.  Ayala has announced that enrollment is complete for Part A of the Phase 2/3 RINGSIDE trial. This trial is testing the oral gamma-secretase inhibitor, AL102, in desmoid tumors. The data from this portion of the trial is expected to be announced in mid-2022, consistent with prior guidance.

    Part A Is Designed To Determine Safety, Efficacy, and Dosing For Part B.  The first part of the RINGSIDE trial enrolled 36 patients to evaluate safety, tolerability, and changes in tumor volume by MRI scans. These data will be used to select the dose for Part B. A previous sub-study tested pharmacokinetics and found no food restrictions were needed …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA



PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Research, News, and Market Data on PDS Biotech

 

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity

FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) —  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data. The data are based on a total of 18 checkpoint inhibitor (CPI) naïve patients from the Company’s ongoing VERSATILE-002 Phase 2 study. The study is being conducted in collaboration with Merck (known as MSD outside the US and Canada) (NCT04260126). The data from the study will be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

The Phase 2 trial studies PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer. The trial is designed to treat both CPI naïve and refractory patients and will assess the primary efficacy endpoint, as well as partial response per RECIST 1.1.  The Company previously announced that it had achieved its preliminary efficacy milestone in the CPI naive arm earlier this month. 

Patients in the trial are treated with KEYTRUDA® 200 mg intravenously every three weeks plus PDS0101 delivered subcutaneously with KEYTRUDA® on cycles of 1-4 and again at cycle 12. An initial safety cohort was assessed during cycle 1 and 21 days following for dose-limiting toxicity, and thereafter for safety and tolerability of the combination.

Highlights from the PDS Biotech’s presentation at the 2022 Multidisciplinary Head and Neck Cancers Symposium regarding the preliminary results of the Phase 2 trial studying PDS0101 in combination with KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer include the absence of dose-limiting toxicities, drug discontinuation related to toxicity, or immune-related adverse events. Subjects received a median of 4 doses of PDS0101 (range 1-5) and a median of 6 doses of KEYTRUDA® (range 1-13). In addition, no treatment-related grade 3 or higher toxicities were reported.

Preliminary safety data has shown that PDS0101 in combination with KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity in the first 18 patients evaluated on the study. Accrual in this study has progressed to Stage 2 for the CPI naïve cohort and is ongoing in Stage 1 for the CPI refractory cohort. The full data set can be found under abstract number 157 at the virtual poster library, here.

Receipt of preliminary results are not necessarily indicative of the final-results of the Phase 2 trial studying PDS0101 in combination with KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.

“We are encouraged by the preliminary safety data of PDS0101 in combination with KEYTRUDA® for patients with recurrent or metastatic HPV16-positive head and neck cancer,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “These data and the preliminary efficacy data continue to support the unique combination of safety and potency of our novel Versamune® platform.” 

In addition to the ongoing VERSATILE-002 Phase 2 trial, PDS Biotech is conducting another Phase 2 clinical study in both second-and third-line treatment for multiple advanced HPV-associated cancers with the National Cancer Institute (NCI) (NCT04287868). A third Phase 2 clinical trial, IMMUNOCERV (NCT04580771), in first-line treatment of locally advanced cervical cancer is being performed with The University of Texas, MD Anderson Cancer Center. In addition, the Company recently announced a fourth Phase 2 trial with Mayo Clinic to study PDS0101 with and without KEYTRUDA® prior to surgery in locally advanced HPV-associated oropharyngeal cancer (NCT05232851). 

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms.

Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.  The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate, and ovarian cancers.  

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium



PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Research, News, and Market Data on PDS Biotech

 

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity

FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) —  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data. The data are based on a total of 18 checkpoint inhibitor (CPI) naïve patients from the Company’s ongoing VERSATILE-002 Phase 2 study. The study is being conducted in collaboration with Merck (known as MSD outside the US and Canada) (NCT04260126). The data from the study will be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.

The Phase 2 trial studies PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer. The trial is designed to treat both CPI naïve and refractory patients and will assess the primary efficacy endpoint, as well as partial response per RECIST 1.1.  The Company previously announced that it had achieved its preliminary efficacy milestone in the CPI naive arm earlier this month. 

Patients in the trial are treated with KEYTRUDA® 200 mg intravenously every three weeks plus PDS0101 delivered subcutaneously with KEYTRUDA® on cycles of 1-4 and again at cycle 12. An initial safety cohort was assessed during cycle 1 and 21 days following for dose-limiting toxicity, and thereafter for safety and tolerability of the combination.

Highlights from the PDS Biotech’s presentation at the 2022 Multidisciplinary Head and Neck Cancers Symposium regarding the preliminary results of the Phase 2 trial studying PDS0101 in combination with KEYTRUDA for the treatment of recurrent or metastatic HPV16-positive head and neck cancer include the absence of dose-limiting toxicities, drug discontinuation related to toxicity, or immune-related adverse events. Subjects received a median of 4 doses of PDS0101 (range 1-5) and a median of 6 doses of KEYTRUDA® (range 1-13). In addition, no treatment-related grade 3 or higher toxicities were reported.

Preliminary safety data has shown that PDS0101 in combination with KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity in the first 18 patients evaluated on the study. Accrual in this study has progressed to Stage 2 for the CPI naïve cohort and is ongoing in Stage 1 for the CPI refractory cohort. The full data set can be found under abstract number 157 at the virtual poster library, here.

Receipt of preliminary results are not necessarily indicative of the final-results of the Phase 2 trial studying PDS0101 in combination with KEYTRUDA® for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.

“We are encouraged by the preliminary safety data of PDS0101 in combination with KEYTRUDA® for patients with recurrent or metastatic HPV16-positive head and neck cancer,” commented Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. “These data and the preliminary efficacy data continue to support the unique combination of safety and potency of our novel Versamune® platform.” 

In addition to the ongoing VERSATILE-002 Phase 2 trial, PDS Biotech is conducting another Phase 2 clinical study in both second-and third-line treatment for multiple advanced HPV-associated cancers with the National Cancer Institute (NCI) (NCT04287868). A third Phase 2 clinical trial, IMMUNOCERV (NCT04580771), in first-line treatment of locally advanced cervical cancer is being performed with The University of Texas, MD Anderson Cancer Center. In addition, the Company recently announced a fourth Phase 2 trial with Mayo Clinic to study PDS0101 with and without KEYTRUDA® prior to surgery in locally advanced HPV-associated oropharyngeal cancer (NCT05232851). 

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms.

Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.  The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate, and ovarian cancers.  

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

Stem Holdings (STMH)(STEM:CA) – Fiscal First Quarter 2022 Results

Thursday, February 24, 2022

Stem Holdings (STMH)(STEM:CA)
Fiscal First Quarter 2022 Results

Stem Holdings Inc is engaged in the purchasing, improving, and leasing of properties and finance assets which are operated by third parties and are used for the cultivation and retail sale of marijuana. Its properties includes 42nd Street, and Mulino Farm which are used for agriculture. The company generates its revenue in the form of rental income from tenants.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    1QFY22 Results. Stem reported net revenue of revenue of $4.2 million compared to $5.3 million last year. The sales decline reflects a decrease in sales resulting from general market conditions. Stem reported a net loss of $4.1 million, or $0.02 per share, for the quarter, including $795,000 of non-cash impairment charges, a $1.75 million loss from discontinued operations, and a $1.7 million gain from the change in the fair value of warrant liability. In 1Q21, Stem recorded a net loss of $3.2 million, or $0.05 per share. Outstanding shares increased to 230.2 million from 69.7 million.

    What’s Next? Interim CEO Hubbard continues to work through putting the Stem house in order, in our opinion, with an ultimate goal of focusing on just the California and Oregon businesses.  Ultimately, we believe Stem either needs to get bigger, which would require additional capital, or sell to a larger entity. Which way the Company will go is uncertain at this time, but we believe Stem does have …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Another Positive Data Point

Thursday, February 24, 2022

Euroseas (ESEA)
Another Positive Data Point

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Time charter on Aegean Express feeder ahead of expectations. Consistent with comments from the recent earnings call, a 36-39 month time charter on the 1,439 TEU Aegean Express Feeder was secured at at an average TCE rate of $41.0k/day. The time charter should generate total revenue of $47.0 million and EBITDA of $36.0 million over the first 36 months, or EBITDA of close to $1.0 million per month beginning in early April.

    Forward 2022 cover of close to 100% at average TCE rates of $31.0k/day creates high visibility.  Recent fixtures pushed 2022 forward cover to almost 100%, and there is only one remaining opportunity this year to move TCE rates closer to market rates. Forward cover represents a solid base for our 2022 EBITDA estimate of $123.6 million, or well above our adjusted 2021 EBITDA of $56.8 million …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Cumulus Media (CMLS) – Favorable Revenue Momentum; Debt Reduction Better Than Expected

Thursday, February 24, 2022

Cumulus Media (CMLS)
Favorable Revenue Momentum; Debt Reduction Better Than Expected

CUMULUS MEDIA, Inc. (NASDAQ: CMLS) is a leading audio-first media and entertainment company delivering premium content to over a quarter billion people every month — wherever and whenever they want it. CUMULUS MEDIA engages listeners with high-quality local programming through 428 owned-and-operated stations across 87 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, the Olympics, the GRAMMYS, the American Country Music Awards, and many other world-class partners across nearly 8,000 affiliated stations through Westwood One, the largest audio network in America; and inspires listeners through its rapidly growing network of original podcasts that are smart, entertaining and thought-provoking. CUMULUS MEDIA provides advertisers with local impact and national reach through on-air, digital, mobile, and voice-activated media solutions, as well as access to integrated digital marketing services, powerful influencers, and live event experiences. CUMULUS MEDIA is the only audio media company to provide marketers with local and national advertising performance guarantees.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Closing the year on target. The company reported full year 2021 revenue of $916.5 million, a 12% YoY increase, which was largely in line with our forecast of $919 million. Adj. EBITDA of $134.9 million outpaced our estimate of $129 million by nearly 5%. Notably, adj. EBITDA was up 66% over the previous year and up 127% year-over-year when excluding political.

    Balance sheet improvements.  For the full year, the company paid down $176.3 million of its long-term debt, including $20 million in Q4. Notably, debt leverage is among the lowest in the industry. Management anticipates that debt leverage will improve to under 3.5 times cash flow by year end, a substantial improvement from previous guidance of 4 times. We are raising our financial assessment from …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Stocks in the Sectors Positively Impacted by Armed Conflict


Image: PxHere (1413412)


The Various Ways to Allocate into “War Investments”

 

The developments between Russia and Ukraine, coupled with international reactions will impact all investment markets over the coming weeks/months. While prices will settle as markets push and pull to determine the appropriate range, the current reaction has created some investments to gain substantially along with those that have been hurt by weakness in their own sectors.

 

A Different Angle on Gold

Gold spiked to its highest level since late 2020. Gold is up by $180 per ounce, or almost 10% since the end of January when it was well below $1800. Gold mining stocks, specifically junior gold miners, have performed even better. As measured by the VanEck Junior Miners ETF (GTXJ), the sector is up 16.89%.

 

 

Current news and company information on junior miners is plentiful on Channelchek. There you can review the research on Great Panther Mining (GPL) which is exceeding, by a wide margin, the performance of gold and the junior mining ETF. Among the many other junior miners worth the attention of investors interested in this sector are: Allegiant Gold Ltd. (AUXXF), Great Bear Resources (GTBAF), and Aurania Resources (AUIAF, ARU:CA).

 

Crude is Up, Who
Benefits?

Oil’s surge to the $100 per barrel mark has brought energy sector stocks up along with it, with a bit of a lag. While crude oil has risen 8.69% since January, the overall energy sector measured by the XLE, which is heavily weighted with giants like Chevron and Exxon, is up over 2% in less than a month while the overall stock market has been sliding rapidly.

Smaller energy stocks, represented in the graph below by the ETF Investco Small-Cap Energy (PSCE) are up twice the larger companies and appear to now be gaining at a more rapid pace than crude.

 

 

Small and microcap energy sector stocks are demonstrating they have more upside potential than larger companies in this sector. Current news and company
information
on smaller energy stocks is plentiful on Channelchek. There you can review the research on Indonesia Energy (INDO) whose price has more than doubled over this period. InPlay Oil Inc. (IPOOF, IPO:CA) has also seen a positive impact.

Overlooked Natural Resources

Palladium and platinum mining stocks, although less talked about, have also surged. A good example is Palladium One Mining Inc. (NKORF, PDM:CA). Since the end of January, the stock has risen 9.68%. The percent performance of Palladium One has spiked double digits over the past two days.

 

Take-Way

Changes and events bring opportunities for investors to reallocate and open themselves to other areas to enrich their portfolios. While at times the more profitable changes are from events that we would prefer not to happen, these events are beyond our control. Whereas one’s portfolio positions are well within their control. For example: Reallocating into construction materials after a devastating hurricane should be done without guilt. The same is true for those investing to take advantage of the current Ukraine/Russia situation.

Channelchek provides data and research on companies that often move by higher percentages when their industry moves. Sign-up to receive our emails to supplement your knowledge in ways missing on other equity research and market information platforms.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Small-Cap Companies and IRA Investments



How Cryptocurrencies, Gold, and Oil Trade When Political Tensions Rise





Index Funds Still May Fall Apart over Time



Trading Accounts for Children

 

Sources

Channelchek.com

www.koyfin.com


 

Stay up to date. Follow us:

 

Chakana Copper Announces Filing Of Technical Report For Previously Reported Inferred Mineral Resources For Soledad Project, Peru



Chakana Copper Announces Filing Of Technical Report For Previously Reported Inferred Mineral Resources For Soledad Project, Peru

Research, News, and Market Data on Chakana Copper

 

Vancouver, B.C., February 23, 2022 – Chakana Copper Corp. (TSX-V: PERU; OTCQB: CHKKF; FRA: 1ZX) (the “Company” or “Chakana”), announced today that the corporation has filed on SEDAR a technical report prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Project (“NI-43-101”) supporting the inferred mineral resource statement for the Soledad Project located in Ancash, Peru. The highlights of the Report were previously announced in a news release dated January 11, 2022, and the effective date of the Report is January 3, 2022. The technical report, titled “Independent Technical Report for the Soledad Copper Project, Ancash Department, Peru”, can be found under the Corporation’s issuer profile at www.sedar.com.

Highlights of the Mineral Resource Estimate:

  • Inferred Resources were estimated for seven breccia pipes that start at surface and extend to an average depth of approximately 300 metres; all zones remain open at depth
  • Inferred Resources of 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper assumed to be extractable by underground mining methods
  • Inferred Resources of 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper assumed to be extractable by open pit mining methods
  • The total initial Inferred Resource contains 191,000 ounces of gold, 11.7 million ounces of silver, and 130 million pounds of copper
  • Opportunities for increasing the Inferred Resources include drill testing numerous additional breccia pipes and other targets identified on the property and extending the known mineralized zones at depth from the current Inferred Resources
  • Only 16 out of 110 (15%) current targets have been tested to date, seven of which are included in the initial Inferred Resource estimate; several of the tested targets are mineralized but not yet included in the initial Inferred Resource as they require additional definition drilling

As previously reported, copper-gold-silver mineralization at the Soledad project is hosted within multiple, vertically extensive tourmaline breccia pipes; important minerals are chalcopyrite, gold, electrum, and tetrahedrite. The resource estimate confirms that the tourmaline breccia pipes at Soledad host significant mineralization with good continuity. The pipes exhibit strong zonation between gold, copper, and silver. Drilling has confirmed the existence of blind breccia pipes that do not crop out a surface (Bx 1 North Zone), and breccia pipes that do crop out coalescing into larger breccias at depth (Huancarama East). The resource model, when combined with our other exploration data sets, helps refine the targeting model that will be used in future exploration drilling campaigns.

“This initial Inferred Resource is a blueprint for the much larger potential of the expanded Soledad project that now covers 4,200 hectares. Our ongoing exploration has defined numerous high-quality drill targets across the broader Soledad project. The Offset (3D) IP geophysical survey we are currently running has been particularly useful in defining targets with larger footprints, consistent with the signature of the larger breccia pipes we have drilled so far. We are excited about testing the broader exploration potential of the project and continuing our ESG programs that have matured over the last couple of years,” stated President and CEO David Kelley.

Mineral resources were estimated by W.F. Tanaka (FAusIMM) and audited and accepted by Dr. Gilles Arseneau (PGeo.) of ARSENEAU Consulting Services Inc. of Vancouver. Resources were estimated for seven tourmaline breccias by ordinary kriging into 5 by 5 by 10 m blocks. Grades were composited to 5 m length and silver composites were capped at 500 g/t for Breccia 1 and 720 g/t for Breccia 6.  

The mineral resources were estimated in accordance with the CIM Definition Standards on Mineral Resources and Mineral Reserves adopted by CIM Council, as amended, and in accordance with National Instrument 43-101.  Near surface mineral resources were reported inside an optimized pit shell and at a dollar equivalent cut-off of US$ 25.00. The dollar equivalent is calculated using a US$1,600 per ounce for gold, US$20 per ounce for silver, and US$3.50 per pound for copper. Metallurgical recoveries were assumed to be 85% for gold, 75% for silver and 90% for copper. Material not captured by the optimized pit shell was assumed to be extractable by underground mining methods if the blocks were above a US$60 cut-off and represented a shape amenable to underground mining below the pit shell. Lead and zinc values also present at Soledad were not considered in the equivalent calculation.

 Based on the above parameters, ACS estimated that the Soledad Project contains 4.8 million tonnes grading 0.72 g/t gold, 61 g/t silver and 0.97% copper amenable to extraction by underground mining methods plus an additional 1.9 million tonnes grading 1.29 g/t gold, 37.1 g/t silver and 0.65% copper amenable to extraction by open pit mining methods.  All resources are classified as Inferred mineral resource as the term is defined by CIM. The QP is not aware of any known legal, political, environmental, or other risks that could materially affect the potential development of the mineral resources or mineral reserves per section 3.4(d) of 43-101.

Soledad Project – Inferred Mineral Resource Statement ACS, effective January 3, 2022  

 Cut -Off (US$)^

Type

Breccia

Tonnes*

Au (g/t)

Ag (g/t)

Cu (%)

$25.00

Open Pit

Breccia 1

486,000

2.46

58.7

1.08

$25.00

Open Pit

Breccia 5

612,000

1.34

22.7

0.44

$25.00

Open Pit

Breccia 6

19,000

0.59

60.7

0.03

$25.00

Open Pit

Breccia 7

76,000

0.65

13.1

0.32

$25.00

Open Pit

Huancarama E

386,000

0.32

40.1

0.42

$25.00

Open Pit

Paloma E

141,000

0.61

18.2

0.35

$25.00

Open Pit

Paloma W

169,000

0.85

44.0

1.12

$25.00

Open Pit Total

All Pipes

1,889,000

1.29

37.1

0.65

$60.00

Underground

Breccia 1

2,170,000

0.65

85.7

1.24

$60.00

Underground

Breccia 5

1,045,000

1.08

13.6

0.86

$60.00

Underground

Breccia 6

114,000

1.28

88.5

0.29

$60.00

Underground

Breccia 7

177,000

0.78

103.7

0.11

$60.00

Underground

Huancarama E

1,185,000

0.52

53.5

0.79

$60.00

Underground

Paloma E

82,000

0.22

23.3

0.68

$60.00

Underground

Paloma W

67,000

0.59

17.0

0.78

$60.00

Underground Total

All Pipes

4,842,000

0.72

61.0

0.97

 

Open Pit + UG

All Pipes

6,731,000

0.88

54.2

0.88

 *Numbers may not add up exactly due to rounding; ^ Cut-offs are based on $1,600/oz gold, $20/oz silver, and $3.50 /lb copper and assumed recoveries of 90% for copper, 85% for gold, and 75% for silver.

Qualified Persons

The Mineral Resource Estimate for the Soledad Project was prepared by Dr. Gilles Arseneau of Arseneau Consulting Services (ACS), an Independent Qualified Person (“QP”) as defined under NI 43-101, who has reviewed and approved the contents of this news release. The technical content of this news release has been reviewed and approved by David Kelley, an officer and a director of Chakana, and a Qualified Person as defined by NI 43-101– Standards of Disclosure of Mineral Projects.

Sampling and Analytical Procedures
All core is cut in half and sampled in one-metre intervals within a secured area until transport in batches to the ALS facility in Callao, Lima, Peru.  Sample batches include certified reference materials, blank, and duplicate samples that are then processed under the control of ALS. All samples are analyzed using the ME-MS41 (ICP technique that provides a comprehensive multi-element overview of the rock geochemistry), while gold is analyzed by AA24 and GRA22 when values exceed 10 g/t by AA24.  Over limit silver, copper, lead, and zinc are analyzed using the OG-46 procedure.

Results of previous drilling and additional information concerning the Project are available on Chakana’s SEDAR profile at www.sedar.com.

ON BEHALF OF THE BOARD

(signed) “David Kelley”  
David Kelley
President and CEO

For further information contact:
Joanne Jobin, Investor Relations Officer
Phone: 647 964 0292
Email: jjobin@chakanacopper.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking Statement Advisory: This release may contain forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Chakana to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward looking statements or information relates to, among other things, the interpretation of the nature of the mineralization at the Soledad copper-gold-silver project (the “Project”), the potential to expand the mineralization, and to develop and grow a resource within the Project, the planning for further exploration work, the ability to de-risk the potential exploration targets, and our belief in the potential for mineralization within unexplored parts of the Project. These forward-looking statements are based on management’s current expectations and beliefs but given the uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward- looking statements or information. The Company disclaims any obligation to update, or to publicly announce, any such statements, events or developments except as required by law.

Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022



Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Research, News, and Market Data on Neovasc

 

VANCOUVER and MINNEAPOLIS – ( NewMediaWire ) – February 24, 2022 – Neovasc Inc. ( NASDAQ ,  TSX : NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on March 10, 2022.

Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13726770. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at  neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit:  www.neovasc.com.

Contacts

Investors

Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media

Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Email: Sean.Leous@icrinc.com

Release – Genco Shipping Trading Limited Announces Fourth Quarter Financial Results



Genco Shipping & Trading Limited Announces Fourth Quarter Financial Results

Research, News, and Market Data on Genco Shipping & Trading

 

Value Strategy Implemented; Declares Dividend of $0.67 per share for Fourth Quarter 2021

Reports Highest Quarterly Earnings Per Share Since 2008

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today reported its financial results for the three months and twelve months ended December 31, 2021.

The following financial review discusses the results for the three months and twelve months ended December 31, 2021 and December 31, 2020.

Fourth Quarter 2021 and Year-to-Date Highlights

  • Implemented its comprehensive value strategy, reducing its cash flow breakeven rate, paving the way for compelling dividends
  • Declared a $0.67 per share dividend for the fourth quarter of 2021, marking the first dividend under Genco’s comprehensive value strategy
    • Represents a ~350% increase from the last quarter’s dividend and the Company’s tenth consecutive quarterly payout
    • Payable on or about March 17, 2022 to all shareholders of record as of March 10, 2022
    • Q4 2021 dividend represents an annualized yield of 14% on Genco’s closing share price as of February 23, 2022
    • We have now declared cumulative dividends totaling $1.725 per share over the last ten quarters, or approximately 9% of the Genco’s closing share price as of February 23, 2022
  • Took delivery of the Genco Mary and the Genco Laddey, two high quality, fuel-efficient Ultramax vessels built in 2022 at Dalian Cosco KHI Ship Engineering Co. Ltd. (DACKS)
    • These two deliveries complete the acquisitions of six Ultramax vessels Genco agreed to acquire from April to July 2021
  • Repaid $203.2 million of debt during 2021, or 45% of the beginning year debt balance, meeting our year-end target of $246 million of debt outstanding, representing a net loan-to-value of 16%1
  • Recorded net income of $90.9 million for the fourth quarter of 2021
    • Basic and diluted earnings per share of $2.16 and $2.13, respectively
    • Adjusted net income1 of $85.0 million or basic and diluted earnings per share of $2.02 and $1.99, respectively, which excludes a $5.8 million gain on sale of vessels
    • Represents our highest quarterly earnings per share result since 2008
  • Voyage revenues totaled $183.3 million and net revenue2 (voyage revenues minus voyage expenses and charter hire expenses) totaled $132.7 million during Q4 2021
    • Our average daily fleet-wide time charter equivalent, or TCE2, for Q4 2021 was $35,200, marking our highest quarterly TCE since 2008
    • For 2021, our average daily fleet-wide TCE2 was $24,402, representing our highest annual TCE since 2010
    • We estimate our TCE to date for Q1 2022 to be $24,215 for 87% of our owned fleet available days, based on both period and current spot fixtures
  • Recorded Adjusted EBITDA of $102.2 million during Q4 2021, which is greater than our Adjusted EBITDA for all of 20202
    • Genco’s 2021 Adjusted EBITDA was $252.9 million, greater than 2019 and 2020 combined and double the 2018 level
  • Maintained a strong liquidity position with $120.5 million of cash as of December 31, 2021, after $203.2 million of debt repayments as well as $108.7 million paid for vessels acquired in the year
  • Transitioned the technical management of nearly all of our vessels to our joint venture with the Synergy Group, GS Shipmanagement, with remaining vessels expected to transition in Q1 2022

John C. Wobensmith, Chief Executive Officer, commented, “2021 proved to be truly transformational for Genco, as we implemented our comprehensive value strategy, creating a unique drybulk vehicle with an attractive risk-reward profile for the benefit of shareholders. Following the announcement of this strategy in April 2021, we spent the balance of the year executing on the blueprint we laid out, focused on growth and financial deleveraging, to position Genco to pay meaningful and sustainable dividends throughout the drybulk cycle. Consistent with our disciplined capital allocation approach, we paid down $203 million of debt in 2021, or 45% of our beginning of the year balance, while taking steps to grow the fleet through the acquisition of six high quality, fuel efficient Ultramax vessels. The combination of these important efforts resulted in a substantial reduction of our cash flow breakeven rate, which we believe will benefit Genco in both the short and long term and enhance our dividend paying ability.”

Mr. Wobensmith, continued, “We are pleased to conclude 2021 with our best quarter in well over a decade, culminating in more than $100 million of EBITDA and a $0.67 per share dividend for the fourth quarter, representing our first dividend under our value strategy. Looking ahead to the first quarter of 2022, we have the majority of our available days booked at over $24,200 per day. This includes earnings generated through our opportunistic container fixtures, which have been generating premium rates above the typical drybulk backhaul route, while further insulating the Company from the softer January rate environment and providing premium positions upon redelivery. Going forward, despite a near-term seasonal decline in freight rates in early 2022, we continue to have a positive outlook on the drybulk market due to the favorable supply and demand balance underpinned by the historically low newbuilding orderbook. Genco remains well positioned to capitalize on these favorable market dynamics utilizing its best-in-class commercial operating platform together with its barbell approach to fleet composition which creates exposure to all drybulk commodities and upside potential. 2021 was a momentous year for the Company, across the board, and we look forward to continue to build on our success in 2022 and beyond.”

Based on estimates from VesselsValue.com and pro forma for delivery of our two Ultramax vessels delivered in January 2022.
We believe the non-GAAP measure presented provides investors with a means of better evaluating and understanding the Company’s operating performance. Please see Summary Consolidated Financial and Other Data below for a further reconciliation.

Comprehensive Value Strategy Implementation in 2021

Genco’s comprehensive value strategy is centered on three key pillars:

  • Paying sizeable quarterly cash dividends to shareholders
  • Low financial leverage, and
  • Opportunistically growing the Company’s asset base

We believe this strategy is a key differentiator for the Company and will drive shareholder value over the long-term creating a compelling risk-reward balance.

Drawing on one of the strongest balance sheets in the industry, Genco utilized a phased in approach to further reduce its debt, grow its fleet and refinance its credit facilities in order to lower its cash flow breakeven levels positioning the Company to pay a sizeable quarterly dividend across diverse market environments. At the same time, we also maintain significant flexibility to grow the fleet through accretive vessel acquisitions. The fourth quarter of 2021 marks the first dividend under the Company’s new corporate strategy and will be payable in March 2022.

Since announcement in April 2021, Genco has implemented this strategy through the following measures:

  • Deleveraging: paid down $203.2 million of debt during 2021, or approximately 45% of our beginning of the year debt balance
  • Refinancing: closed on a new global credit facility to increase flexibility, improve key terms and lower cash flow breakeven rates
  • Revolver: our $450 million credit facility has a substantial revolver in place with $184.8 million of availability as of December 31, 2021
  • Growth: acquired six modern, fuel efficient Ultramaxes
  • Securing revenue: opportunistically fixed various period time charterers to secure cash flows and de-risk recent acquisitions as shown in the following table:
Vessel Type DWT Year Built Rate Duration Min Expiration
Genco Liberty Capesize 180,387 2016 $ 31,000 10-13 months Mar-22
Baltic Bear Capesize 177,717 2010 $ 32,000 10-14 months Mar-22
Baltic Wolf Capesize 177,752 2010 $ 30,250 22-28 months Jun-23
Genco Maximus Capesize 169,025 2009 $ 27,500 24-30 months Sep-23
Genco Vigilant Ultramax 63,498 2015 $ 17,750 11-13 months Sep-22
Genco Freedom Ultramax 63,671 2015 $ 23,375 20-23 months Mar-23
Baltic Hornet Ultramax 63,574 2014 $ 24,000 20-23 months Apr-23
Baltic Wasp Ultramax 63,389 2015 $ 25,500 23-25 months Jun-23
             
Genco Claudius Capesize 169,001 2010 94% of BCI 11-14 months Jan-23
Genco Resolute Capesize 181,060 2015 121% of BCI 11-14 months Jan-23
             

Our debt outstanding as of December 31, 2021 was $246 million following voluntary debt repayments totaling $59 million in the fourth quarter of 2021. Importantly, following these repayments, we have no mandatory debt amortization payments until 2026. Regardless of this favorable mandatory amortization schedule, we plan to continue to voluntarily pay down our debt with the medium-term objective of reducing our net debt to zero and a longer-term goal of zero debt. Specifically, as previously announced, Genco paid down an additional $8.75 million of debt during the first quarter of 2022.

Dividend policy

For the fourth quarter of 2021, Genco declared a cash dividend of $0.67 per share. This represents a ~350% increase from the $0.15 per share paid during the previous quarter and marks the first quarterly dividend under our new comprehensive value strategy.

As part of Genco’s value strategy, the Board of Directors adopted a new quarterly dividend policy for dividends payable commencing in the first quarter of 2022 in respect to the Company’s financial results for the fourth quarter of 2021.  Under the new quarterly dividend policy, the amount available for quarterly dividends is to be calculated based on the following formula, which includes the Q4 2021 dividend calculation and estimated amounts for calculation of the dividend for the first quarter of 2022: 

Dividend calculation Q4 2021 actual Q1 2022 estimates
Net revenue $ 132.70   Fixtures + market
Operating expenses   (31.79 ) (31.63 )
Operating cash flow $ 100.92    
Less: debt repayments   (59.00 ) (8.75 )
Less: capex for dydocking/BWTS/ESDs   (2.92 ) (5.90 )
Less: reserve   (10.75 ) (10.75 )
Cash flow distributable as dividends $ 28.25   Sum of the above
Number of shares to be paid dividends   42.4   42.4  
Dividend per share $ 0.67    
Numbers in millions except per share amounts    
     

For purposes of the foregoing calculation, operating cash flow is defined as net revenue (consisting of voyage revenue less voyage expenses and charter hire expenses), less operating expenses (consisting of vessel operating expenses, general and administrative expenses other than non-cash restricted stock expenses, technical management fees, and interest expense other than non-cash deferred financing costs).  During the fourth quarter of 2021, we paid down $59.00 million of debt on a voluntary basis. Drydocking, ballast water treatment system and energy saving device costs related to three vessels that drydocked during the fourth quarter. Furthermore, our reserve for Q4 2021 was $10.75 million as previously announced in advance. Anticipated uses for the reserve include, but are not limited to, vessel acquisitions, debt repayments, and general corporate purposes. In order to set aside funds for these purposes, we plan to set the reserve on a quarterly basis for the subsequent quarter and is anticipated to be based on future quarterly debt repayments and interest expenseThe quarterly reserve for the first quarter of 2022 is expected to be $10.75 million. The reserve was determined based on $8.75 million for voluntary debt repayments anticipated to be made in Q2 2022 as well as estimated cash interest expense on our debt and remains subject to our Board of Directors’ discretion. The quarterly debt repayment and reserve will be reassessed on a quarterly basis in advance by the Board of Directors and management. Estimated expenses, debt repayments, and capital expenditures for Q1 2022 are estimates presented for illustrative purposes. The amounts shown will vary based on actual results. Maintaining a quarterly reserve as well as optionality for the uses of the reserve are important factors of our corporate strategy that are intended to allow Genco to retain liquidity to take advantage of a variety of market conditions.

The Board expects to reassess the payment of dividends as appropriate from time to time. The quarterly dividend policy and declaration and payment of dividends are subject to legally available funds, compliance with law and contractual obligations and the Board of Directors’ determination that each declaration and payment is at the time in the best interests of the Company and its shareholders. Our quarterly dividend policy and declaration and payment of dividends are subject to legally available funds, compliance with applicable law and contractual obligations (including our credit facilities) and the Board of Directors’ determination that each declaration and payment is at the time in the best interests of the Company and its shareholders after its review of our financial performance.

Genco’s active commercial operating platform and fleet deployment strategy

Overall, we utilize a portfolio approach towards revenue generation through a combination of short-term, spot market employment as well as opportunistically booking longer term coverage. Our fleet deployment strategy currently remains weighted towards short-term fixtures, which provide us with optionality on our sizeable fleet. Our barbell approach towards fleet composition enables Genco to gain exposure to both the major and minor bulk commodities with a fleet whose cargoes carried align with global commodity trade flows. This approach continues to serve us well given the upside potential in major bulk rates together with the relative stability of minor bulk rates.

Based on current fixtures to date, our estimated TCE to date for the first quarter of 2022 on a load-to-discharge basis is presented below. Our estimated Q1 TCE based on current fixtures, while lower than Q4 2021, highlights our proactive approach of booking coverage ahead of the seasonally softer first quarter market. In 2021, we selectively booked period time charter coverage for approximately one to two years on four Capesize and four Ultramax vessels. We view these fixtures as part of our portfolio approach to fixture activity and prudent to take advantage of in the firm freight rate environment.

Estimated net TCE – Q1 2022 to Date
Vessel Type Period Spot Fleet-wide % Fixed
Capesize $ 27,955 $ 23,568 $ 24,612 93%
Ultramax/Supramax $ 21,093 $ 24,586 $ 23,947 83%
Fleet-wide $ 24,301 $ 24,193 $ 24,215 87%
         

Given our eight vessels fixed on one to two year period time charters, we have provided a TCE breakout of the period time charters as well as the spot trading fixtures in the first quarter to date. Actual rates for the first quarter will vary based upon future fixtures.

Fleet Update

The Company took delivery of the remaining two 2022-built, high specification, fuel efficient Ultramax vessels it agreed to acquire in May 2021, namely the Genco Mary and the Genco Laddey. Both of these vessels were delivered to Genco on January 6, 2022.

As for vessel divestitures, we completed the sale of the Genco Provence on November 2, 2021, for gross proceeds of $13.25 million. With this sale, we have now divested the oldest vessel in our fleet and in the process have avoided drydocking capex costs scheduled for 2022 of approximately $0.8 million.

Financial Review: 2021 Fourth Quarter

The Company recorded net income for the fourth quarter of 2021 of $90.9 million, or $2.16 and $2.13 basic and diluted earnings per share, respectively. Comparatively, for the three months ended December 31, 2020, the Company recorded a net loss of $65.9 million, or $1.57 basic and diluted net loss per share.

The Company’s revenues increased to $183.3 million for the three months ended December 31, 2021, as compared to $95.5 million recorded for the three months ended December 31, 2020, primarily due to higher rates achieved by both our major and minor bulk vessels, as well as our third-party time chartered-in vessels. The average daily time charter equivalent, or TCE, rates obtained by the Company’s fleet was $35,200 per day for the three months ended December 31, 2021 as compared to $13,167 per day for the three months ended December 31, 2020. During the fourth quarter of 2021, the drybulk market remained firm as Capesize rates reached a peak of $86,953 on October 7, 2021. While freight rates retreated from these high levels, the earnings environment remained robust for the quarter led by strong global commodity demand together with low net fleet growth and continued fleet-wide inefficiencies. During the first quarter of 2022, the drybulk freight market seasonally declined primarily due to weather related issues in Brazil limiting cargo availability, the timing of newbuilding vessel deliveries as well as the timing of the Lunar New Year and the Beijing Olympics.

Voyage expenses were $36.6 million for the three months ended December 31, 2021 compared to $33.4 million during the prior year period. This increase was primarily due to higher bunker expenses, partially offset by the operation of fewer vessels. Vessel operating expenses increased to $22.5 million for the three months ended December 31, 2021 from $21.1 million for the three months ended December 31, 2020, due to higher crew expenses as a result of COVID-19 related expenses and disruptions. General and administrative expenses increased to $6.8 million for the fourth quarter of 2021 compared to $4.9 million for the fourth quarter of 2020, primarily due to higher personnel related expenses as well as higher legal and professional fees. Depreciation and amortization expenses decreased to $14.8 million for the three months ended December 31, 2021 from $15.5 million for the three months ended December 31, 2020, primarily due to a decrease in depreciation for certain vessels in our fleet that were impaired during 2020.

Daily vessel operating expenses, or DVOE, amounted to $5,766 per vessel per day for the fourth quarter of 2021 compared to $4,726 per vessel per day for the fourth quarter of 2020. This increase is primarily attributable to higher crew expenses as a result of COVID-19 related expenses and disruptions, which amounted to $770 per vessel per day, as well as higher lubricant-related expenses. COVID related expenses were higher than anticipated during the quarter as a result of a global escalation of cases and the timing of our crew changes. We believe daily vessel operating expenses are best measured for comparative purposes over a 12 month period in order to take into account all of the expenses that each vessel in our fleet will incur over a full year of operation. Based on estimates provided by our technical managers, our DVOE budget for the first quarter of 2022 is $5,825 per vessel per day on a fleet-wide basis including an estimate for COVID-19 related expenses. The potential impacts of COVID-19 are beyond our control and are difficult to predict due to uncertainties surrounding the pandemic.

Apostolos Zafolias, Chief Financial Officer, commented, “During 2021, our unrelenting focus was on improving the strength of our balance sheet, taking steps to further reduce our leverage and breakeven levels and enhancing our earnings power and dividend potential. We are pleased to have achieved important objectives for the year, underpinning our value strategy, as highlighted by our closing of a new, attractive $450 million credit facility, our $203 million reduction of debt and our opportunistic vessel purchases. We enter the year with a cash flow breakeven among the lowest in the industry and significant financial flexibility including a sizeable cash position. Maintaining balance sheet strength while optimizing the risk-reward balance for our shareholders remains a priority for Genco as we continue to execute our value strategy.”

Financial Review: Twelve Months 2021

The Company recorded net income of $182.0 million or $4.33 and $4.27 basic and diluted net earnings per share for the twelve months ended December 31, 2021, respectively. This compares to a net loss of $225.6 million or $5.38 basic and diluted net loss per share for the twelve months ended December 31, 2020. Net income for the twelve months ended December 31, 2021 includes a $4.9 million gain on sale of vessels as well as a $4.4 million loss on debt extinguishment. Net loss for the twelve months ended December 31, 2020 includes $208.9 million in non-cash vessel impairment charges and a $1.9 million loss on sale of vessels. Revenues increased to $547.1 million for the twelve months ended December 31, 2021 compared to $355.6 million for the twelve months ended December 31, 2020, primarily due to higher rates achieved by our fleet as well as our third-party time chartered-on vessels, which was partially offset by the operation of fewer vessels in our fleet. Voyage expenses decreased to $146.2 million for the twelve months ended December 31, 2021 from $157.0 million for the same period in 2020. TCE rates obtained by the Company increased to $24,402 per day for the twelve months ended December 31, 2021 from $10,221 per day for the twelve months ended December 31, 2020. Total operating expenses for the twelve months ended December 31, 2021 and 2020 were $346.0 million and $558.9 million, respectively. General and administrative expenses for the twelve months ended December 31, 2021 increased to $24.5 million as compared to $21.3 million in the same period of 2020, primarily due to higher personnel related expenses, as well as higher legal and professional fees. DVOE was $5,409 in 2021 versus $4,612 in 2020. The increase in daily vessel operating expense was predominantly due to higher crew expenses as a result of COVID-19 related expenses and disruptions. EBITDA for the twelve months ended December 31, 2021 amounted to $253.4 million compared to $(139.0) million during the prior period. During the twelve months of 2021 and 2020, EBITDA included non-cash impairment charges, gains and losses on sale of vessels as well as a loss on debt extinguishment as mentioned above. Excluding these items, our adjusted EBITDA would have amounted to $252.9 million and $71.8 million, for the respective periods.

Liquidity and Capital Resources

Cash Flow

Net cash provided by operating activities for the years ended December 31, 2021 and 2020 was $231.1 million and $36.9 million, respectively.  This increase in cash provided by operating activities was primarily due to higher rates achieved by our major and minor bulk vessels, changes in working capital, as well as a decrease in drydocking related expenditures and interest expense.

Net cash used in investing activities during the year ended December 31, 2021 was $67.6 million as compared to $37.4 million net cash provided by investing activities during the year ended December 31, 2020.  This fluctuation was primarily due to the purchase of four Ultramax vessels which delivered during the third quarter of 2021, as well as deposits made for the two Ultramax vessels that were delivered during January 2022. Additionally, there was a decrease in the net proceeds from the sale of vessels.  These fluctuations were partially offset by a decrease in scrubber related expenses and purchase of other fixed assets during 2021 as compared to 2020.

Net cash used in financing activities during the years ended December 31, 2021 and 2020 was $222.7 million and $56.9 million, respectively.  The increase was primarily due to the refinancing of the $495 Million Credit Facility and the $133 Million Credit Facility with the $450 Million Credit Facility on August 31, 2021. During 2021, the increase in total net cash used in financing activities related to our credit facilities was $156.6 million as compared to 2020. Additionally, there was a $5.6 million increase in deferred financing costs paid in relation to the $450 Million Credit Facility during 2021. Lastly, there was a $3.6 million increase in the payment of dividends during 2021 as compared to 2020.

Capital Expenditures

We make capital expenditures from time to time in connection with vessel acquisitions. As of February 24, 2022, Genco Shipping & Trading Limited’s fleet consists of 17 Capesize, 15 Ultramax and 12 Supramax vessels with an aggregate capacity of approximately 4,635,000 dwt and an average age of 10.0 years.

In addition to acquisitions that we may undertake, we will incur additional capital expenditures due to special surveys and drydockings. Furthermore, we plan to upgrade a portion of our fleet with energy saving devices and apply high performance paint systems to our vessels in order to reduce fuel consumption and emissions. We estimate our capital expenditures related to drydocking, including capitalized costs incurred during drydocking related to vessel assets and vessel equipment, ballast water treatment system costs, fuel efficiency upgrades and scheduled off-hire days for our fleet for 2022 to be:

  Q1 2022 Q2 2022 Q3 2022 Q4 2022
Estimated Drydock Costs (1) $3.8 million $10.1 million $3.9 million
Estimated BWTS Costs (2) $1.2 million $4.6 million $1.5 million
Estimated Fuel Efficiency Upgrade Costs (3) $0.9 million $6.1 million $1.3 million $0.8 million
Total Estimated Costs $5.9 million $20.9 million $6.7 million $0.8 million
Estimated Offhire Days (4) 99 234 103
         

(1) Estimates are based on our budgeted cost of drydocking our vessels in China. Actual costs will vary based on various factors, including where the drydockings are actually performed. We expect to fund these costs with cash on hand. These costs do not include drydock expense items that are reflected in vessel operating expenses.

(2) Estimated costs associated with the installation of ballast water treatment systems is expected to be funded with cash on hand.

(3) Estimated costs associated with the installation of fuel efficiency upgrades are expected to be funded with cash on hand.

(4) Actual length will vary based on the condition of the vessel, yard schedules and other factors. The estimated offhire days per sector scheduled for Q1 2022 consists of 36 days for one Capesize, 42 days for three Ultramaxes and 21 days for one Supramax. Estimated offhire days for 2022 relate to 15 vessels drydocking during the year.

Summary Consolidated Financial and Other Data

The following table summarizes Genco Shipping & Trading Limited’s selected consolidated financial and other data for the periods indicated below.

        Three Months Ended
December 31, 2021
  Three Months Ended
December 31, 2020
  Twelve Months Ended
December 31, 2021
  Twelve Months Ended
December 31, 2020
        (Dollars in thousands, except share and per share data)   (Dollars in thousands, except share and per share data)
        (unaudited)   (unaudited)    
INCOME STATEMENT DATA:              
Revenues:              
  Voyage revenues $ 183,277     $ 95,495     $ 547,129     $ 355,560  
    Total revenues   183,277       95,495       547,129       355,560  
                     
Operating expenses:              
  Voyage expenses   36,610       33,435       146,182       156,985  
  Vessel operating expenses   22,467       21,088       82,089       87,420  
  Charter hire expenses   13,964       4,780       36,370       10,307  
  General and administrative expenses (inclusive of nonvested stock amortization   6,838       4,912       24,454       21,266  
  expense of $0.6 million, $0.5 million, $2.3 million and $2.0 million , respectively)              
  Technical management fees   1,213       1,645       5,612       6,961  
  Depreciation and amortization   14,822       15,549       56,231       65,168  
  Impairment of vessel assets         74,225             208,935  
  (Gain) loss on sale of vessels   (5,818 )     1,012       (4,924 )     1,855  
    Total operating expenses   90,096       156,646       346,014       558,897  
                     
                     
Operating income (loss)   93,181       (61,151 )     201,115       (203,337 )
                     
Other income (expense):              
  Other income (expense)   101       49       541       (851 )
  Interest income   10       79       154       1,028  
  Interest expense   (2,402 )     (4,898 )     (15,357 )     (22,413 )
  Loss on debt extinguishment               (4,408 )      
    Other expense, net   (2,291 )     (4,770 )     (19,070 )     (22,236 )
                     
                     
Net income (loss) $ 90,890     $ (65,921 )   $ 182,045     $ (225,573 )
                     
  Less: Net income attributable to noncontrolling interest   38             38   $ $  
                     
Net income (loss) attributable to Genco Shipping & Trading Limited $ 90,852     $ (65,921 )   $ 182,007   $ $ (225,573 )
                     
Net earnings (loss) per share – basic $ 2.16     $ (1.57 )   $ 4.33     $ (5.38 )
                     
Net earnings (loss) per share – diluted $ 2.13     $ (1.57 )   $ 4.27     $ (5.38 )
                     
Weighted average common shares outstanding – basic   42,102,187       41,933,926       42,060,996       41,907,597  
                     
Weighted average common shares outstanding – diluted   42,709,594       41,933,926       42,588,871       41,907,597  
                     
                     
                     
            December 31, 2021   December 31, 2020    
BALANCE SHEET DATA (Dollars in thousands):     (unaudited)        
                     
Assets              
  Current assets:              
    Cash and cash equivalents     $ 114,573     $ 143,872      
    Restricted cash       5,643       35,492      
    Due from charterers, net       20,116       12,991      
    Prepaid expenses and other current assets       9,935       10,856      
    Inventories       24,563       21,583      
    Vessels held for sale             22,408      
  Total current assets       174,830       247,202      
                     
  Noncurrent assets:              
    Vessels, net of accumulated depreciation of $253,005 and $204,201, respectively       981,141       919,114      
    Deposits on vessels       18,543            
    Vessels held for exchange             38,214      
    Deferred drydock, net       14,275       14,689      
    Fixed assets, net       7,237       6,393      
    Operating lease right-of-use assets       5,495       6,882      
    Restricted cash       315       315      
    Fair value of derivative instruments       1,166            
  Total noncurrent assets       1,028,172       985,607      
                     
  Total assets     $ 1,203,002     $ 1,232,809      
                     
Liabilities and Equity              
  Current liabilities:              
    Accounts payable and accrued expenses     $ 29,956     $ 22,793      
    Current portion of long-term debt             80,642      
    Deferred revenue       10,081       8,421      
    Current operating lease liabilities       1,858       1,765      
  Total current liabilities       41,895       113,621      
                     
  Noncurrent liabilities              
    Long-term operating lease liabilities       6,203       8,061      
    Contract liability             7,200      
    Long-term debt, net of deferred financing costs of $7,771 and $9,653, respectively       238,229       358,933      
  Total noncurrent liabilities       244,432       374,194      
                     
  Total liabilities       286,327       487,815      
                     
  Commitments and contingencies              
                     
  Equity:              
    Common stock       419       418      
    Additional paid-in capital       1,702,166       1,713,406      
    Accumulated other comprehensive income       825            
    Accumulated deficit       (786,823 )     (968,830 )    
  Total Genco Shipping & Trading Limited shareholders’ equity       916,587       744,994      
    Noncontrolling interest       88            
  Total equity       916,675       744,994      
                     
  Total liabilities and equity     $ 1,203,002     $ 1,232,809      
                     
                     
            Twelve Months Ended
December 31, 2021
  Twelve Months Ended
December 31, 2020
   
STATEMENT OF CASH FLOWS (Dollars in thousands):     (unaudited)        
                     
Cash flows from operating activities              
    Net income (loss)     $ 182,045     $ (225,573 )    
    Adjustments to reconcile net income (loss) to net cash provided by operating activities:              
    Depreciation and amortization       56,231       65,168      
    Amortization of deferred financing costs       3,536       3,903      
    Amortization of fair market value of time charters acquired       (4,263 )          
    Right-of-use asset amortization       1,387       1,359      
    Amortization of nonvested stock compensation expense       2,267       2,026      
    Impairment of vessel assets             208,935      
    (Gain) loss on sale of vessels       (4,924 )     1,855      
    Loss on debt extinguishment       4,408            
    Amortization of premium on derivative       197            
    Interest rate cap premium payment       (240 )          
    Insurance proceeds for protection and indemnity claims       988       569      
    Insurance proceeds for loss of hire claims             78      
    Change in assets and liabilities:              
      (Increase) decrease in due from charterers       (7,125 )     710      
      Increase in prepaid expenses and other current assets       (783 )     (1,938 )    
      (Increase) decrease in inventories       (2,980 )     5,625      
      Increase (decrease) in accounts payable and accrued expenses       5,405       (17,355 )    
      Increase in deferred revenue       1,660       1,794      
      Decrease in operating lease liabilities       (1,765 )     (1,677 )    
      Deferred drydock costs incurred       (4,925 )     (8,583 )    
    Net cash provided by operating activities       231,119       36,896      
                     
Cash flows from investing activities              
    Purchase of vessels and ballast water treatment systems, including deposits       (115,680 )     (4,485 )    
    Purchase of scrubbers (capitalized in Vessels)       (199 )     (10,973 )    
    Purchase of other fixed assets       (1,585 )     (4,580 )    
    Net proceeds from sale of vessels       49,473       56,993      
    Insurance proceeds for hull and machinery claims       418       484      
    Net cash (used in) provided by investing activities       (67,573 )     37,439      
                     
Cash flows from financing activities              
    Proceeds from the $450 Million Credit Facility       350,000            
    Repayments on the $450 Million Credit Facility       (104,000 )          
    Proceeds from the $133 Million Credit Facility             24,000      
    Repayments on the $133 Million Credit Facility       (114,940 )     (9,160 )    
    Proceeds from the $495 Million Credit Facility             11,250      
    Repayments on the $495 Million Credit Facility       (334,288 )     (72,686 )    
    Investment by non-controlling interest       50            
    Cash dividends paid       (13,463 )     (9,847 )    
    Payment of deferred financing costs       (6,053 )     (462 )    
    Net cash used in financing activities       (222,694 )     (56,905 )    
                     
Net (decrease) increase in cash, cash equivalents and restricted cash       (59,148 )     17,430      
                     
Cash, cash equivalents and restricted cash at beginning of period       179,679       162,249      
Cash, cash equivalents and restricted cash at end of period     $ 120,531     $ 179,679      
                     
                     
                     
        Three Months Ended
December 31, 2021
           
Adjusted Net Income Reconciliation (unaudited)            
Net income attributable to Genco Shipping & Trading Limited $ 90,852              
  + Gain on sale of vessels   (5,818 )            
      Adjusted net income $ 85,034              
                     
      Adjusted net earnings per share – basic $ 2.02              
      Adjusted net earnings per share – diluted $ 1.99              
                     
      Weighted average common shares outstanding – basic   42,102,187              
      Weighted average common shares outstanding – diluted   42,709,594              
                     
      Weighted average common shares outstanding – basic as per financial statements   42,102,187              
      Dilutive effect of stock options   380,055              
      Dilutive effect of restricted stock units   227,352              
      Weighted average common shares outstanding – diluted as adjusted   42,709,594              
                     
                     
        Three Months Ended
December 31, 2021
  Three Months Ended
December 31, 2020
  Twelve Months Ended
December 31, 2021
  Twelve Months Ended
December 31, 2020
        (Dollars in thousands)   (Dollars in thousands)
EBITDA Reconciliation: (unaudited)   (unaudited)
  Net income (loss) attributable to Genco Shipping & Trading Limited $ 90,852     $ (65,921 )   $ 182,007     $ (225,573 )
  + Net interest expense   2,392       4,819       15,203       21,385  
  + Depreciation and amortization   14,822       15,549       56,231       65,168  
      EBITDA (1) $ 108,066     $ (45,553 )   $ 253,441     $ (139,020 )
                     
  + Impairment of vessel assets         74,225             208,935  
  + (Gain) loss on sale of vessels   (5,818 )     1,012       (4,924 )     1,855  
  + Loss on debt extinguishment               4,408        
      Adjusted EBITDA $ 102,248     $ 29,684     $ 252,925     $ 71,770  
                     
                     
        Three Months Ended   Twelve Months Ended
        December 31, 2021   December 31, 2020   December 31, 2021   December 31, 2020
FLEET DATA: (unaudited)   (unaudited)
Total number of vessels at end of period   42       47       42       47  
Average number of vessels (2)   42.4       48.5       41.6       51.8  
Total ownership days for fleet (3)   3,897       4,462       15,177       18,957  
Total chartered-in days (4)   352       400       1,472       1,216  
Total available days for fleet (5)   4,122       4,751       16,412       19,636  
Total available days for owned fleet (6)   3,770       4,350       14,940       18,420  
Total operating days for fleet (7)   4,060       4,637       16,165       19,204  
Fleet utilization (8)   97.4 %     96.8 %     97.9 %     97.1 %
                     
                     
AVERAGE DAILY RESULTS:              
Time charter equivalent (9) $ 35,200     $ 13,167     $ 24,402     $ 10,221  
Daily vessel operating expenses per vessel (10)   5,766       4,726       5,409       4,612  
                     
        Three Months Ended   Twelve Months Ended
        December 31, 2021   December 31, 2020   December 31, 2021   December 31, 2020
FLEET DATA: (unaudited)   (unaudited)
Ownership days              
Capesize   1,564.0       1,564.0       6,205.0       6,222.0  
Panamax                     64.8  
Ultramax   1,196.0       560.0       3,716.8       2,204.0  
Supramax   1,136.7       1,696.0       5,027.2       7,176.0  
Handymax                      
Handysize         642.0       227.5       3,290.0  
Total   3,896.7       4,462.0       15,176.5       18,956.8  
                     
Chartered-in days              
Capesize                      
Panamax                      
Ultramax   62.6       182.4       450.1       557.1  
Supramax   247.6       203.7       979.9       567.2  
Handymax                     14.5  
Handysize   42.2       14.3       42.2       77.4  
Total   352.4       400.4       1,472.2       1,216.2  
                     
Available days (owned & chartered-in fleet)              
Capesize   1,535.2       1,547.7       6,118.6       6,158.2  
Panamax                     64.4  
Ultramax   1,194.5       718.2       4,079.2       2,657.5  
Supramax   1,350.4       1,865.6       5,944.9       7,443.1  
Handymax                     14.5  
Handysize   42.2       619.2       269.8       3,298.2  
Total   4,122.3       4,750.7       16,412.5       19,635.9  
                     
Available days (owned fleet)              
Capesize   1,535.2       1,547.7       6,118.6       6,158.2  
Panamax                     64.4  
Ultramax   1,131.9       535.8       3,629.1       2,100.4  
Supramax   1,102.8       1,661.9       4,965.0       6,875.9  
Handymax                      
Handysize         604.9       227.6       3,220.8  
Total   3,769.9       4,350.3       14,940.3       18,419.7  
                     
Operating days              
Capesize   1,530.9       1,521.6       6,080.1       6,093.0  
Panamax                     60.1  
Ultramax   1,163.4       712.9       4,015.2       2,642.8  
Supramax   1,323.4       1,824.1       5,835.7       7,338.1  
Handymax                     14.5  
Handysize   42.2       578.3       233.5       3,055.9  
Total   4,060.1       4,636.9       16,164.5       19,204.4  
                     
Fleet utilization              
Capesize   97.9 %     97.3 %     98.8 %     98.2 %
Panamax                     92.7 %
Ultramax   96.6 %     98.8 %     97.6 %     99.3 %
Supramax   97.5 %     96.8 %     97.6 %     97.6 %
Handymax                     100.0 %
Handysize   100 %     93.2 %     86.6 %     92.2 %
Fleet average   97.4 %     96.8 %     97.9 %     97.1 %
                     
Average Daily Results:              
Time Charter Equivalent              
Capesize $ 40,620     $ 17,460     $ 27,293     $ 14,977  
Panamax                     4,948  
Ultramax   30,581       14,089       22,169       10,320  
Supramax   32,455       10,514       23,235       7,957  
Handymax                      
Handysize         8,822       8,116       5,987  
Fleet average   35,200       13,167       24,402       10,221  
                     
Daily vessel operating expenses              
Capesize $ 5,519     $ 5,232     $ 5,572     $ 5,106  
Panamax                     3,290  
Ultramax   4,783       4,247       5,062       4,606  
Supramax   7,091       4,648       5,443       4,456  
Handymax                      
Handysize         4,105       5,856       3,994  
Fleet average   5,766       4,726       5,409       4,612  
                     
                     

1) EBITDA represents net income (loss) attributable to Genco Shipping & Trading Limited plus net interest expense, taxes, and depreciation and amortization. EBITDA is included because it is used by management and certain investors as a measure of operating performance. EBITDA is used by analysts in the shipping industry as a common performance measure to compare results across peers. Our management uses EBITDA as a performance measure in consolidating internal financial statements and it is presented for review at our board meetings. We believe that EBITDA is useful to investors as the shipping industry is capital intensive which often results in significant depreciation and cost of financing. EBITDA presents investors with a measure in addition to net income to evaluate our performance prior to these costs. EBITDA is not an item recognized by U.S. GAAP (i.e. non-GAAP measure) and should not be considered as an alternative to net income, operating income or any other indicator of a company’s operating performance required by U.S. GAAP. EBITDA is not a measure of liquidity or cash flows as shown in our consolidated statement of cash flows. The definition of EBITDA used here may not be comparable to that used by other companies.
2) Average number of vessels is the number of vessels that constituted our fleet for the relevant period, as measured by the sum of the number of days each vessel was part of our fleet during the period divided by the number of calendar days in that period.
3) We define ownership days as the aggregate number of days in a period during which each vessel in our fleet has been owned by us. Ownership days are an indicator of the size of our fleet over a period and affect both the amount of revenues and the amount of expenses that we record during a period.
4) We define chartered-in days as the aggregate number of days in a period during which we chartered-in third-party vessels.
5) We define available days as the number of our ownership days and chartered-in days less the aggregate number of days that our vessels are off-hire due to familiarization upon acquisition, repairs or repairs under guarantee, vessel upgrades or special surveys. Companies in the shipping industry generally use available days to measure the number of days in a period during which vessels should be capable of generating revenues.
6) We define available days for the owned fleet as available days less chartered-in days.
7) We define operating days as the number of our total available days in a period less the aggregate number of days that the vessels are off-hire due to unforeseen circumstances. The shipping industry uses operating days to measure the aggregate number of days in a period during which vessels actually generate revenues.
8) We calculate fleet utilization as the number of our operating days during a period divided by the number of ownership days plus chartered-in days less drydocking days.
9) We define TCE rates as our voyage revenues less voyage expenses and charter hire expenses, divided by the number of the available days of our owned fleet during the period. TCE rate is a common shipping industry performance measure used primarily to compare daily earnings generated by vessels on time charters with daily earnings generated by vessels on voyage charters, because charterhire rates for vessels on voyage charters are generally not expressed in per-day amounts while charterhire rates for vessels on time charters generally are expressed in such amounts. Our estimated TCE for the first quarter of 2022 is based on fixtures booked to date. Actual results may vary based on the actual duration of voyages and other factors. Accordingly, we are unable to provide, without unreasonable efforts, a reconciliation of estimated TCE for the first quarter to the most comparable financial measures presented in accordance with GAAP.

        Three Months Ended
December 31, 2021
  Three Months Ended
December 31, 2020
  Twelve Months Ended
December 31, 2021
  Twelve Months Ended
December 31, 2020
Total Fleet (unaudited)   (unaudited)
Voyage revenues (in thousands) $ 183,277     $ 95,495     $ 547,129     $ 355,560  
Voyage expenses (in thousands)   36,610       33,435       146,182       156,985  
Charter hire expenses (in thousands)   13,964       4,780       36,370       10,307  
          132,703       57,280       364,577       188,268  
                     
Total available days for owned fleet   3,770       4,350       14,940       18,420  
Total TCE rate $ 35,200     $ 13,167     $ 24,402     $ 10,221  
                     
                     

10) We define daily vessel operating expenses to include crew wages and related costs, the cost of insurance expenses relating to repairs and maintenance (excluding drydocking), the costs of spares and consumable stores, tonnage taxes and other miscellaneous expenses. Daily vessel operating expenses are calculated by dividing vessel operating expenses by ownership days for the relevant period.

About Genco Shipping & Trading Limited

Genco Shipping & Trading Limited is a U.S. based drybulk ship owning company focused on the seaborne transportation of commodities globally. We provide a full-service logistics solution to our customers utilizing our in-house commercial operating platform, as we transport key cargoes such as iron ore, grain, steel products, bauxite, cement, nickel ore among other commodities along worldwide shipping routes. Our wholly owned high quality, modern fleet of dry cargo vessels consists of the larger Capesize (major bulk) and the medium-sized Ultramax and Supramax vessels (minor bulk) enabling us to carry a wide range of cargoes. We make capital expenditures from time to time in connection with vessel acquisitions. As of February 24, 2022, Genco Shipping & Trading Limited’s fleet consists of 17 Capesize, 15 Ultramax and 12 Supramax vessels with an aggregate capacity of approximately 4,635,000 dwt and an average age of 10.0 years.

The following table reflects Genco’s fleet list as of February 24, 2022: 

  Vessel DWT Year Built
Capesize    
1 Genco Resolute 181,060 2015
2 Genco Endeavour 181,060 2015
3 Genco Liberty 180,387 2016
4 Genco Defender 180,377 2016
5 Genco Constantine 180,183 2008
6 Genco Augustus 180,151 2007
7 Baltic Lion 179,185 2012
8 Genco Tiger 179,185 2011
9 Genco London 177,833 2007
10 Baltic Wolf 177,752 2010
11 Genco Titus 177,729 2007
12 Baltic Bear 177,717 2010
13 Genco Tiberius 175,874 2007
14 Genco Commodus 169,098 2009
15 Genco Hadrian 169,025 2008
16 Genco Maximus 169,025 2009
17 Genco Claudius 169,001 2010
Ultramax    
1 Genco Freedom 63,671 2015
2 Baltic Hornet 63,574 2014
3 Genco Vigilant 63,498 2015
4 Genco Enterprise 63,473 2016
5 Baltic Mantis 63,470 2015
6 Baltic Scorpion 63,462 2015
7 Genco Magic 63,446 2014
8 Baltic Wasp 63,389 2015
9 Genco Constellation 63,310 2017
10 Genco Mayflower 63,304 2017
11 Genco Madeleine 63,166 2014
12 Genco Weatherly 61,556 2014
13 Genco Mary 61,085 2022
14 Genco Laddey 61,085 2022
15 Genco Columbia 60,294 2016
Supramax    
1 Genco Hunter 58,729 2007
2 Genco Auvergne 58,020 2009
3 Genco Rhone 58,018 2011
4 Genco Ardennes 58,018 2009
5 Genco Brittany 58,018 2010
6 Genco Languedoc 58,018 2010
7 Genco Pyrenees 58,018 2010
8 Genco Bourgogne 58,018 2010
9 Genco Aquitaine 57,981 2009
10 Genco Warrior 55,435 2005
11 Genco Predator 55,407 2005
12 Genco Picardy 55,257 2005
       

 Conference Call Announcement

Genco Shipping & Trading Limited will hold a conference call on Thursday, February 24, 2022 at 8:30 a.m. Eastern Time to discuss its 2021 fourth quarter financial results. The conference call and a presentation will be simultaneously webcast and will be available on the Company’s website, www.GencoShipping.com. To access the conference call, dial (646) 828-8193 or (888) 220-8451 and enter passcode 9610869. A replay of the conference call can also be accessed for two weeks by dialing (888) 203-1112 or (719) 457-0820 and entering the passcode 9610869. The Company intends to place additional materials related to the earnings announcement, including a slide presentation, on its website prior to the conference call.

Website Information

We intend to use our website, www.GencoShipping.com, as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in our website’s Investor Relations section. Accordingly, investors should monitor the Investor Relations portion of our website, in addition to following our press releases, SEC filings, public conference calls, and webcasts. To subscribe to our e-mail alert service, please click the “Receive E-mail Alerts” link in the Investor Relations section of our website and submit your email address. The information contained in, or that may be accessed through, our website is not incorporated by reference into or a part of this document or any other report or document we file with or furnish to the SEC, and any references to our website are intended to be inactive textual references only.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements use words such as “anticipate,” “budget,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance.  These forward-looking statements are based on our management’s current expectations and observations. Included among the factors that, in our view, could cause actual results to differ materially from the forward looking statements contained in this report are the following: (i) declines or sustained weakness in demand in the drybulk shipping industry; (ii)  weakness or declines in drybulk shipping rates; (iii) changes in the supply of or demand for drybulk products, generally or in particular regions; (iv) changes in the supply of drybulk carriers including newbuilding of vessels or lower than anticipated scrapping of older vessels; (v) changes in rules and regulations applicable to the cargo industry, including, without limitation, legislation adopted by international organizations or by individual countries and actions taken by regulatory authorities; (vi) increases in costs and expenses including but not limited to: crew wages, insurance, provisions, lube oil, bunkers, repairs, maintenance, general and administrative expenses, and management fee expenses; (vii) whether our insurance arrangements are adequate; (viii) changes in general domestic and international political conditions; (ix) acts of war, terrorism, or piracy; (x) changes in the condition of the Company’s vessels or applicable maintenance or regulatory standards (which may affect, among other things, our anticipated drydocking or maintenance and repair costs) and unanticipated drydock expenditures; (xi) the Company’s acquisition or disposition of vessels; (xii) the amount of offhire time needed to complete maintenance, repairs, and installation of equipment to comply with applicable regulations on vessels and the timing and amount of any reimbursement by our insurance carriers for insurance claims, including offhire days; (xiii) the completion of definitive documentation with respect to charters; (xiv) charterers’ compliance with the terms of their charters in the current market environment; (xv) the extent to which our operating results are affected by weakness in market conditions and freight and charter rates; (xvi) our ability to maintain contracts that are critical to our operation, to obtain and maintain acceptable terms with our vendors, customers and service providers and to retain key executives, managers and employees; (xvii) completion of documentation for vessel transactions and the performance of the terms thereof by buyers or sellers of vessels and us; (xviii) the relative cost and availability of low sulfur and high sulfur fuel, worldwide compliance with sulfur emissions regulations that took effect on January 1, 2020 and our ability to realize the economic benefits or recover the cost of the scrubbers we have installed.; (xix) our financial results for the year ending December 31, 2021 and other factors relating to determination of the tax treatment of dividends we have declared; (xx) the financial results we achieve for each quarter that apply to the formula under our new dividend policy, including without limitation the actual amounts earned by our vessels and the amounts of various expenses we incur, as a significant decrease in such earnings or a significant increase in such expenses may affect our ability to carry out our new value strategy; (xxi) the exercise of the discretion of our Board regarding the declaration of dividends, including without limitation the amount that our Board determines to set aside for reserves under our dividend policy; (xxii) the duration and impact of the COVID-19 novel coronavirus epidemic, which may negatively affect general global and regional economic conditions; our ability to charter our vessels at all and the rates at which are able to do so; our ability to call on or depart from ports on a timely basis or at all; our ability to crew, maintain, and repair our vessels, including without limitation the impact diversion of our vessels to perform crew rotations may have on our revenues, expenses, and ability to consummate vessel sales, expense and disruption to our operations that may arise from the inability to rotate crews on schedule, and delay and added expense we may incur in rotating crews in the current environment; our ability to staff and maintain our headquarters and administrative operations; sources of cash and liquidity; our ability to sell vessels in the secondary market, including without limitation the compliance of purchasers and us with the terms of vessel sale contracts, and the prices at which vessels are sold; and other factors relevant to our business described from time to time in our filings with the Securities and Exchange Commission; and (xxiv) other factors listed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent reports on Form 8-K and Form 10-Q. Our ability to pay dividends in any period will depend upon various factors, including the limitations under any credit agreements to which we may be a party, applicable provisions of Marshall Islands law and the final determination by the Board of Directors each quarter after its review of our financial performance, market developments, and the best interests of the Company and its shareholders. The timing and amount of dividends, if any, could also be affected by factors affecting cash flows, results of operations, required capital expenditures, or reserves. As a result, the amount of dividends actually paid may vary. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Apostolos Zafolias
Chief Financial Officer
Genco Shipping & Trading Limited
(646) 443-8550

Source: Genco Shipping & Trading Limited

Using Warren Buffetts SEC Filing as an Oracle



It’s Officially Warren Buffett Season – Hints on What to Expect

 

Berkshire Hathaway’s annual report is set to be released Saturday, February 26th.  As is customary, it will be accompanied by the famous CEO, Warren Buffett’s Letter to Shareholders. Using past years as an indicator, investors can expect a lot of news and views surrounding the report and letter. For the next two months, investors can expect more media interviews with Buffett or Berkshire’s number two man Charlie Munger. These all have the potential to move stocks and even crypto prices. The Berkshire Hathaway annual meeting will be in person this year on April 30th. The presentations will be viewable live on Yahoo Finance.

As investors enter “Buffett season” the time of year when Warren Buffett, one of the most recognized and highly successful investors, shares his thoughts and wisdom related to current markets, an early read of Berkshire’s actions can be helpful for investors – and we just received one. Berkshire Hathaway’s (BRK/A, BRK/B) fourth-quarter 13F of all public market transactions was just filed last week. Below we highlight some of the more notable shifts in the company’s portfolio, these changes may provide an early read on presentations at the annual meeting.

Using
Berkshires 13F as an Oracle

Berkshire Hathaway’s fourth-quarter 13F was filed on February 14. There are two new names of publicly-traded companies in the portfolio. The combined equity securities of Berkshire’s portfolio represent a fraction of company assets since Berkshire wholly owns large brand name companies such as Fruit of the Loom, Geico, and Duracell. The filing shows Berkshire’s $331 billion investment portfolio consists of 44 companies, one company more than the previous quarter.

The top 5 holdings account for over 79% of the total securities portfolio. These include Apple (AAPL), Bank of America (BAC), American Express (AXP), Coca-Cola (KO), and Kraft Heinz (KHC). The significant holdings in Apple, Bank of America, and American Express cause the portfolio, relative to the S&P 500 Index to be more highly weighted in technology, staples, and the financial sector.

Overall, the total securities portfolio carries a slightly more expensive valuation than the S&P 500 while having achieved higher profitability (ROE) and exhibiting lower debt ratios and higher credit ratings.

In the quarter, there were two new additions: Activision Blizzard (ATVI) and Liberty Media – Formula One (FWONK). Microsoft announced a deal to buy ATVI for $95.00 per share in cash on January 18, 2022. Berkshire also added a position of Nu Holdings (NU), which it backed before the firm became public late last year.

Berkshire added to its position in Chevron (CVX), Liberty Media – Liberty SiriusXM (LSXMA), RH (RH), Floor & Decor-A (FND). FND was a new purchase in the last quarter, with the position increased this quarter. The CVX holding was also increased in the third quarter. RH was last increased in the second quarter of 2021.

Reduced can be seen in Berkshire’s holdings of Kroger (KR), Charter Communications (CHTR), Visa (V), Mastercard (MA), Abbvie (ABBV), Royalty Pharma (RPRX), Bristol-Myers Squibb (BMY), and Marsh & McClennan (MMC). Many of the pharmaceuticals being reduced were added in the first half of 2020 and served the portfolio well. The reduced credit card positions began in the third quarter of 2021, with Berkshire previously trimming its positions in V and MA back in the second quarter of 2020.

Teva Pharmaceutical (TEVA) and Sirius XM Holdings (SIRI) were eliminated from the portfolio in the fourth quarter.

Take-Away

Individual stocks can make big moves with just a small utterance from highly-followed investors. Warren Buffett is the ultimate “highly-followed” investor. Over the upcoming days and weeks investors will be treated to more than just utterances.

All of this comes at a time when the investment climate is shifting. Sign-up for Channelchek to receive emails containing research and articles to help provide actionable ideas for your portfolio.

 

Suggested Reading



Cathie Wood Thinks if There is No Blood in Your Street, You Should Move



Michael Burry’s Public Investments in SPACs, Prisons, and Electric Hogs





One Great Protection Inherent in SPACs for Investors



The Last Thing You’ll Ever Need to Read About the Berkshire Hathaway Meeting Until 2021 (Seriously!)

 

Sources

https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001067983

https://www.berkshirehathaway.com/news/jan2722.pdf

https://13f.info/manager/0001067983-berkshire-hathaway-inc

https://en.wikipedia.org/wiki/Berkshire_Hathaway

https://www.forbes.com/sites/bill_stone/2022/02/14/berkshire-hathaways-portfolio-moves-in-the-fourth-quarter/?sh=2fead431685c

https://stockzoa.com/fund/berkshire-hathaway-inc/

https://whalewisdom.com/filer/berkshire-hathaway-inc


 

Stay up to date. Follow us: